BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11205462)

  • 41. Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model.
    Romaguera JE; McLaughlin P; North L; Dixon D; Silvermintz KB; Garnsey LA; Velasquez WS; Hagemeister FB; Cabanillas F
    J Clin Oncol; 1991 May; 9(5):762-9. PubMed ID: 1707956
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Follicular lymphomas: assessment of prognostic factors in 127 patients followed for 10 years.
    Bastion Y; Berger F; Bryon PA; Felman P; Ffrench M; Coiffier B
    Ann Oncol; 1991 Feb; 2 Suppl 2():123-9. PubMed ID: 2049309
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Follicle centre lymphoma: treatment results for stage I and II].
    Neumann H; Blanck H; Koch R; Fiedler S; Lesche A; Herrmann T
    Strahlenther Onkol; 2003 Dec; 179(12):840-6. PubMed ID: 14652673
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant?
    Seyfarth B; Kuse R; Sonnen R; Glass B; Schmitz N; Dreger P
    Ann Hematol; 2001 Jul; 80(7):398-405. PubMed ID: 11529465
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ocular adnexal diffuse large B-cell lymphoma: a multicenter international study.
    Munch-Petersen HD; Rasmussen PK; Coupland SE; Esmaeli B; Finger PT; Graue GF; Grossniklaus HE; Honavar SG; Khong JJ; McKelvie PA; Mulay K; Prause JU; Ralfkiaer E; Sjö LD; Sniegowski MC; Vemuganti GK; Heegaard S
    JAMA Ophthalmol; 2015 Feb; 133(2):165-73. PubMed ID: 25393033
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.
    Morschhauser F; Radford J; Van Hoof A; Vitolo U; Soubeyran P; Tilly H; Huijgens PC; Kolstad A; d'Amore F; Gonzalez Diaz M; Petrini M; Sebban C; Zinzani PL; van Oers MH; van Putten W; Bischof-Delaloye A; Rohatiner A; Salles G; Kuhlmann J; Hagenbeek A
    J Clin Oncol; 2008 Nov; 26(32):5156-64. PubMed ID: 18854568
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Therapy of non-Hodgkin's lymphoma.
    Coffey J; Hodgson DC; Gospodarowicz MK
    Eur J Nucl Med Mol Imaging; 2003 Jun; 30 Suppl 1():S28-36. PubMed ID: 12692688
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Primary cutaneous non-Hodgkin's lymphoma with aggressive histology: inferior outcome is associated with peripheral T-cell type and elevated lactate dehydrogenase, but not extent of cutaneous involvement.
    Visco C; Medeiros LJ; Jones D; Smith T; Rodriguez MA; McLaughlin P; Romaguera J; Cabanillas F; Sarris AH
    Ann Oncol; 2002 Aug; 13(8):1290-9. PubMed ID: 12181254
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Conjunctival Lymphoma--An International Multicenter Retrospective Study.
    Kirkegaard MM; Rasmussen PK; Coupland SE; Esmaeli B; Finger PT; Graue GF; Grossniklaus HE; Honavar SG; Khong JJ; McKelvie PA; Mulay K; Prause JU; Ralfkiaer E; Sjö LD; Toft PB; Vemuganti GK; Thuro BA; Curtin J; Heegaard S
    JAMA Ophthalmol; 2016 Apr; 134(4):406-14. PubMed ID: 26891973
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nodular histiocytic lymphoma, emphasizing results of stage I disease treated by radiotherapy. A report of the Japan Lymphoma Radiation Therapy Study Group (JLRTG).
    Hayabuchi N; Jingu K; Masaki N; Niibe H; Morita K; Horiuchi J; Kaneta K; Watanabe S
    Am J Clin Oncol; 1990 Dec; 13(6):501-6. PubMed ID: 2239805
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil].
    Qin Y; Shi YK; He XH; Yang JL; Yang S; Yu YX; Li B; Wang QL; Zhou LQ; Sun Y
    Ai Zheng; 2006 Apr; 25(4):481-5. PubMed ID: 16613685
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score.
    Peters AC; Duan Q; Russell JA; Duggan P; Owen C; Stewart DA
    Leuk Lymphoma; 2011 Nov; 52(11):2124-9. PubMed ID: 21740097
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma.
    Luminari S; Ferrari A; Manni M; Dondi A; Chiarenza A; Merli F; Rusconi C; Tarantino V; Tucci A; Vitolo U; Kovalchuk S; Angelucci E; Pulsoni A; Arcaini L; Angrilli F; Gaidano G; Stelitano C; Bertoldero G; Cascavilla N; Salvi F; Ferreri AJM; Vallisa D; Marcheselli L; Federico M
    J Clin Oncol; 2018 Mar; 36(7):689-696. PubMed ID: 29095677
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience.
    Ganti AK; Weisenburger DD; Smith LM; Hans CP; Bociek RG; Bierman PJ; Vose JM; Armitage JO
    Ann Oncol; 2006 Jun; 17(6):920-7. PubMed ID: 16524969
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term follow-up of patients with Stage III follicular lymphoma treated with primary radiotherapy at Stanford University.
    Murtha AD; Rupnow BA; Hansosn J; Knox SJ; Hoppe R
    Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):3-15. PubMed ID: 11163492
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas.
    Rohatgi N; LaRocca RV; Bard V; Sethuraman G; Foon KA
    Am J Hematol; 2002 Jul; 70(3):181-5. PubMed ID: 12111762
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
    Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
    Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Follicular lymphoma: expanding therapeutic options.
    Ganti AK; Bociek RG; Bierman PJ; Enke CA; Vose JM; Armitage JO
    Oncology (Williston Park); 2005 Feb; 19(2):213-28; discussion 228, 233-6, 239. PubMed ID: 15770890
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma.
    Wilder RB; Rodriguez MA; Ha CS; Pro B; Hess MA; Cabanillas F; Cox JD
    Cancer; 2001 Jun; 91(12):2440-6. PubMed ID: 11413536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.